Results 51 to 60 of about 7,402 (202)

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

open access: yesHIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini   +24 more
wiley   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

open access: yes, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

open access: yesHIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito   +13 more
wiley   +1 more source

Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials [PDF]

open access: yes, 2014
Background. Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill ...
Dowdy, David W.   +9 more
core   +4 more sources

Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Immunocompromised individuals experience an impaired immune function due to conditions that might be either congenital or acquired over the course of their lives. Epidemiological studies often rely on clinical definitions which, in some cases, benefit from being translated into machine‐readable algorithms for application to electronic health ...
Judit Riera‐Arnau   +62 more
wiley   +1 more source

Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis. [PDF]

open access: yes, 2017
Background Accurately determining renal function is essential for clinical management of HIV patients. Classically, it has been evaluated by estimating glomerular filtration rate (eGFR) with the MDRD-equation, but today there is evidence that the new ...
Agüero Santangelo, Fernando   +9 more
core   +1 more source

Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism

open access: yesDrugs in R&D, 2023
Background and Objective Esmethadone (dextromethadone; d-methadone; S-methadone (+)-methadone; REL-1017) is the opioid inactive dextro-isomer of racemic methadone.
Nicola Ferri   +10 more
doaj   +1 more source

Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort [PDF]

open access: yes, 2019
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected ...
Abeli C.   +155 more
core   +4 more sources

Comparative effectiveness of dolutegravir + lamivudine versus three‐drug regimens in Swedish clinical practice: a nationwide study

open access: yesJournal of the International AIDS Society, Volume 29, Issue 3, March 2026.
Abstract Introduction HIV guidelines recommend switching from a three‐drug regimen (3DR) to dolutegravir + lamivudine (DTG+3TC) for eligible individuals. This retrospective national cohort study used Swedish InfCareHIV registry data to evaluate long‐term outcomes of adults with HIV RNA <50 copies/ml who switched to DTG+3TC or a guideline‐recommended ...
Erik Sörstedt   +9 more
wiley   +1 more source

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS

open access: yesHIV/AIDS: Research and Palliative Care, 2016
Jordi Navarro, Adrian Curran Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain Abstract: Efficacy is the main objective of antiretroviral treatment and adherence is
Navarro J, Curran A
doaj  

Home - About - Disclaimer - Privacy